Evidence map›Paper›PMID 36237908›Full record

ArticleFrontiers in cardiovascular medicine2022

First peripheral drug-eluting stent clinical results from China: 1-year outcomes of the Zilver PTX China study.

Wei Ye, Tanja Böhme, Weiguo Fu, Changwei Liu, Xiaoming Zhang, Peng Liu, Jiwei Zhang, Yinghua Zou, Xinwu Lu, Aaron E Lottes and 3 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02171962 (Evaluation of the Zilver® PTX® Drug-Eluting Peripheral Stent for Treatment of Lesions of the Above-the-Knee Femoropopliteal Artery), which is not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02171962 nacompletednot on this map

Evaluation of the Zilver® PTX® Drug-Eluting Peripheral Stent for Treatment of Lesions of the Above-the-Knee Femoropopliteal Artery

TypeinterventionalSponsorCook Group IncorporatedRan2014 to 2017Enrolled178ConditionsPeripheral Artery DiseaseArmsZilver® PTX® Drug-Eluting Peripheral Stent
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 3 countries.

Wei YeVascular Surgical Department, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China.
Tanja BöhmeDepartment of Angiology, Universitaets-Herz-Zentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany.
Weiguo FuDepartment of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Changwei LiuDepartment of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Xiaoming ZhangDepartment of Vascular Surgery, Peking University People's Hospital, Beijing, China.
Peng LiuDepartment of Vascular Surgery, China-Japan Friendship Hospital, Beijing, China.
Jiwei ZhangDepartment of Vascular Surgery, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China.
Yinghua ZouDepartment of IR and Vascular Surgery, Peking University, Beijing, China.
Xinwu LuDepartment of Vascular Surgery, Shanghai 9th People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Aaron E LottesWeldon School of Biomedical Engineering, Purdue University, West Lafayette, IN, United States.
Erin E O'LearyCook Research Incorporated, West Lafayette, IN, United States.
Thomas ZellerDepartment of Angiology, Universitaets-Herz-Zentrum Freiburg-Bad Krozingen, Bad Krozingen, Germany.
Michael D DakeDepartment of Medical Imaging, The University of Arizona, Tucson, AZ, United States.
Peking Union Medical College Hospital · CNPeking University · CNUniversitäts-Herzzentrum Freiburg-Bad Krozingen · DEBanner - University Medical Center Tucson · USChina-Japan Friendship Hospital · CNCook Research (United States) · USPurdue University West Lafayette · USRenji Hospital · CNShanghai Jiao Tong University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The benefit of using the Zilver PTX drug-eluting stent (DES) in superficial femoral artery (SFA) lesions has been demonstrated in multiple clinical studies. This prospective, multicenter study evaluated the 1-year safety and effectiveness of the DES for the treatment of femoropopliteal lesions in a Chinese patient population. Methods: Patients with a single Results: In this study, 178 patients with symptomatic peripheral artery disease were enrolled at nine institutions in China. The average lesion length was 79.0 ± 48.6 mm (range 14.8-245.4 mm) and 50.0% of lesions were total occlusions. The 1-year primary patency rate was 81.9%. Covariate analysis revealed that lesion length ( Conclusion: This study showed promising short-term results for the treatment of SFA lesions with Zilver PTX DES in Chinese patients. Unique identifier: ClinicalTrials.gov, identifier: NCT02171962.

Indexed as

drug-eluting stentpaclitaxel-eluting stentperipheral artery diseaseperipheral vascular diseasesuperficial femoral artery

Identifiers

PMID36237908
PMCPMC9551216
OpenAlexW4297311841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.